| |
Pharmacokinetic Parameter (mean ± SD)
|
|---|
|
Antibiotic
|
CLT (L/hr)
|
Vc (L)
|
Fraction unbound (%)*
|
Intercompartment Rate Constants (h-1)
|
Absorption Rate Constant (h-1)
|
|---|
| | | | |
K12
|
K21
|
K01
|
|---|
|
Amoxicillin ± clavulanate
|
22.2677 ± 5.8091
|
14.0622 ± 5.5932
|
80 ± 2
|
1.77 ± 2.27
|
1.91 ± 1.12
|
0.93 ± 0.49
|
|
Cefaclor
|
43.1513 ± 13.0045
|
29.3195 ± 8.3441
|
75 ± 5
|
0.45 ± 0.12
|
1.15 ± 0.35
|
2.61 ± 0.78
|
| |
CL_F (L/hr)
| | | | | |
|
Azithromycin
|
122 ± 33
|
---
|
---
| | | |
|
Levofloxacin
|
10.5 ± 1.48
|
---
|
62-76
| | | |
|
Gatifloxacin
|
12.54 ± 1.27
|
---
|
78-82
| | | |
|
Moxifloxacin
|
14.9 ± 1.18
|
---
|
49.5-70
| | | |
- * Fraction unbound estimates simulated as a mean (SD) Gaussian distribution for amoxicillin, co-amoxiclav, and cefaclor. Estimates simulated as a range for the FQ and azithromycin, where each value in the range has an equal likelihood of occurring.
- CLT = total body clearance reported from 2-compartment model; Vc = volume of the central compartment reported from 2-compartment model; K12 = intercompartment rate constant between first and second compartments; K21 = intercompartment rate constant between second and first compartments; K01 = absorption rate constant; CL_F = clearance accounting for bioavailability reported in pharmacokinetic analyses.
